BOLU İLİNDEKİ TESTİS KANSERLİ HASTALARIN RETROSPEKTİF ANALİZİ

Uğur ÜYETÜRK; Ümmügül ÜYETÜRK; Ahmet METİN

Makale detayları

BOLU İLİNDEKİ TESTİS KANSERLİ HASTALARIN RETROSPEKTİF ANALİZİ

Yazarlar:

Uğur ÜYETÜRK | Ümmügül ÜYETÜRK | Ahmet METİN

Yayıncı:

Yozgat Bozok University

Dergi:

Bozok Medical Journal 2015 Vol.5 Issue 1, pp.41-46

Belge Tipi:

Makale

Yayın Tarihi:

2/2015

Belge Dili:

Türkçe

Document ID (Org No.):

2000898053

Sıklık:

Aylık

eISSN:

2148-2438

pISSN:

2146-4006

Anahtar kelimeler:

Özet:

 

Objective: ATesticular cancer (Tca) consists of approximately %20 of urogenital malignancy in men, and approximately %1 to 2 of all male malignancies. Tca is the most common solid tumor in males aged between 15 to 35 years. There are many risk factors related to Tca such as cryptorchidism, testicular microlithiasis, klinefelter and Down syndrome. 95% of Tca is derived from germinal tissue. Germ cell tumor is classified into two groups: seminomatous and nonseminomatous (embryonic carcinoma cell, teratoma, choriocarcinoma, yolk sac tumor). In this study, we aimed to evaluate general characteristics and treatment modalities of the patients with diagnosis of Tca living in our region.Material and Methods: Demographic characteristics and treatment modalities of the patients with Tca followed at Bolu Abant İzzet Baysal University Medicine Faculty, Medical Oncology outpatient clinic between 01.01.2012 and 30.07.2013 were evaluated retrospectively.Results: Fifteen patients with median age of 31  were included in the study. As the first compliant, 11 patients (%74) reported a mass within the testis, 2 patients (%13) reported pain, and 2 patients (%13) claimed both pain and mass. The tumor was unilateral in 14 patients and bilateral in 1 patient. The median tumor size was 4  cm. 7 patients had seminomatous histology and 7 patients had nonseminomatous histology. The patient with bilateral tumor had seminomatous histology in the right testis and nonseminomatous histology in the left testis. After orchiectomy, two patients with seminomatous stage IA were given carboplatin and one patient was followed without chemotherapy; two patients with stage IB were given carboplatin and one patient was followed without chemotherapy; one patient with stage IIB was given bleomycin, etoposide, cisplatin (BEP) chemotherap; 2 patients with nonseminomatous stage IA were followed without chemotherapy; the patientswith stage II and above were given BEP chemotherapy. Conclusion: We concluded that our results were in consistent with the literature. We assumed that further studies are needed in other part of the country to obtain the data of Turkish population.

 

ÖZETAmaç: Testis kanseri (Tca) erkeklerde görülen ürogenital malignitelerin yaklaşık %20’sini, tüm erkek maligni-telerinin yaklaşık %1-2’sini oluşturmasına rağmen, 15-35 yaş arası en sık görülen solid kanserlerdir. Kriptorşi- dizm, testiküler mikrolitiasis, Klinifelter ve Down Sendromu Tca için risk faktörleridir. Tca’lerinin %95’i germinal dokudan köken alır. Bu tümörler seminomatöz ve nonseminomatöz (embriyonel hücreli karsinom, teratom, koryokarsinom, yolk kesesi tümörü) olarak iki gruba ayrılmaktadır. Biz bu çalışmada, bölgemizde yaşayan Tca tanısı almış hastaların genel özelliklerini ve tedavi seçeneklerini retrospektif olarak değerlendirmeyi amaçladık. Gereç ve Yöntemler: 01.01.2012-30.07.2013 tarihleri arasında Bolu Abant İzzet Baysal Üniversitesi Tıp Fakülte- si, tıbbi onkoloji polikliniğine başvuran Tca’li hastaların demografik özellikleri ve tedavi seçenekleri retrospektif olarak değerlendirildi.Bulgular: Bu süre içinde median yaşı 31(22-45) yıl olan 15 hastanın başvurduğu bulundu. İlk başvuru şikayeti olarak 11’nunda (%74) testiste kitle, 2’sinde (%13) ağrı, 2’sinde (%13) kitle ile birlikte ağrı vardı. Hastaların14’ünde tümör unilateral, 1’inde bilateraldi. Tümör boyutu ortalama 4(0.8-10) cm’di. Hastaların tümörlerinin7’si seminomatöz, 7’si nonseminomatöz ve bilateral tümörlü hastanın sağ testisi seminomatöz, diğeri nonse- minomatöz histolojiye sahipti. Orşiektomi sonrası seminomatöz evre IA olan 2 hastaya karboplatin, 1 hastaya izlem, evre IB olan 2 hastaya karboplatin, 1 hastaya izlem, evre IIB olan 1 hastaya bleomisin, etoposid, sisplatin (BEP) kemoterapisi verildiği, nonseminomatöz evre IA 2 hastaya izlem, evre II ve üzeri hastalara ise BEP kemo- terapisi verildiği görüldü.Sonuç: Bolu ilindeki Tca’li hastaların değerlendirildiği bu retrospektif analiz sonuçları literatür ile uyumlu bu- lundu. Türkiye verilerini elde edebilmek için diğer illerinde dahil edileceği, daha fazla hasta katılımıyla yapılacak çalışmaların gerekli olduğunu düşünmekteyiz.Anahtar kelimeler: Testis kanseri; Kemoterapi; OrşiektomiABSTRACTObjective: ATesticular cancer (Tca) consists of approximately %20 of urogenital malignancy in men, andapproximately %1 to 2 of all male malignancies. Tca is the most common solid tumor in males aged between15 to 35 years. There are many risk factors related to Tca such as cryptorchidism, testicular microlithiasis, klinefelter and Down syndrome. 95% of Tca is derived from germinal tissue. Germ cell tumor is classified into two groups: seminomatous and nonseminomatous (embryonic carcinoma cell, teratoma, choriocarcinoma, yolk sac tumor). In this study, we aimed to evaluate general characteristics and treatment modalities of the patients with diagnosis of Tca living in our region.Material and Methods: Demographic characteristics and treatment modalities of the patients with Tca followed at Bolu Abant İzzet Baysal University Medicine Faculty, Medical Oncology outpatient clinic between01.01.2012 and 30.07.2013 were evaluated retrospectively.Results: Fifteen patients with median age of 31 (22-45) were included in the study. As the first compliant, 11 patients (%74) reported a mass within the testis, 2 patients (%13) reported pain, and 2 patients (%13) claimed both pain and mass. The tumor was unilateral in 14 patients and bilateral in 1 patient. The median tumor size was 4 (0.8-10) cm. 7 patients had seminomatous histology and 7 patients had nonseminomatous histology. The patient with bilateral tumor had seminomatous histology in the right testis and nonseminomatous histology in the left testis. After orchiectomy, two patients with seminomatous stage IA were given carboplatin and one patient was followed without chemotherapy; two patients with   stage IB were given carboplatin and one patient was followed without chemotherapy; one patient with stage IIB was given bleomycin, etoposide, cisplatin (BEP) chemotherap; 2 patients with nonseminomatous stage IA were followed without chemotherapy; the patientswith stage II and above were given BEP chemotherapy.Conclusion: We concluded that our results were in consistent with the literature. We assumed that further studies are needed in other part of the country to obtain the data of Turkish population.Keywords: Testicular cancer; Chemotherapy; Orchiectomy.

Makale detayları

BOLU İLİNDEKİ TESTİS KANSERLİ HASTALARIN RETROSPEKTİF ANALİZİ

Yazarlar: Uğur ÜYETÜRK | Ümmügül ÜYETÜRK | Ahmet METİN

Yayıncı: Yozgat Bozok University

Dergi: Bozok Medical Journal 2015 Vol.5 Issue 1, pp.41-46

Belge Tipi: Makale

Yayın Tarihi: 2/2015

Belge Dili: Türkçe

Document ID (Org No.): 2000898053

Sıklık: Aylık

eISSN: 2148-2438

pISSN: 2146-4006

Testis kanseri

Kemoterapi; Orşiektomi

Sayı

Yazarlar:

Uğur ÜYETÜRK | Ümmügül ÜYETÜRK | Ahmet METİN

Yayıncı:

Yozgat Bozok University

Dergi:

Bozok Medical Journal 2015 Vol.5 Issue 1, pp.41-46

Belge Tipi:

Makale

Yayın Tarihi:

2/2015

Belge Dili:

Türkçe

Document ID (Org No.):

2000898053

Sıklık:

Aylık

eISSN:

2148-2438

pISSN:

2146-4006